Milner Therapeutics Institute announced as finalist for 2025 OBN Award

The Milner Therapeutics Institute has been announced as a finalist for a 2025 OBN Award in the category of Most Impactful Industry Collaboration!

The Institute has been recognised for theFunctional Genomics Screening Laboratory (FGSL), a collaboration between our Institute at the University of Cambridge, the Medical Research Council (MRC) and AstraZeneca, which aims to combine know-how and experience to accelerate the development of biomarkers and therapeutics for diseases through functional interrogation of the genome at scale. As part of the Human Functional Genomics Initiative, the FGSL forms collaborations to explore how genes impact on complex phenotypes in development and disease.

The OBN Awards, now in its 17th year, is a highly regarded awards programme for the Life Sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the industry. The awards shine a light on companies at all stages of development, recognising inspirational leadership, exciting innovation, novel approaches to unmet clinical need, outstanding company progression, and the delivery of tangible outcomes.

This recognition follows on from our previous success at the OBN Awards in 2021, when the Institute won in the category of Most Impactful Business Support Organisation, reflecting our ongoing commitment to collaboration and innovation across the life sciences ecosystem.

The winners will be announced at the OBN Awards ceremony on Wednesday 26th November 2025 at The Royal Lancaster, London.